Our results verified peri-tumoral infiltration level of CD68+ macrophages compared to paired tumor samples of no BTS group and HL group, indicating macrophage-based therapeutics like CD47 blockade that promotes macrophage phagocytosis 40 being possibly feasible. The gene discussed is CD47; the disease is Hodgkins lymphoma.